Replies to post #803827 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

sentiment_stocks, I do agree that methylated GBM patients were helped more by DCVax-L than unmethylated patients were.

But all GBM patients were helped to extend overall survival (OS) when treated with DCVax-L. That include methylated and unmethylated patients.

I think that to say “DCVax-L does not help unmethylated GBM patients on its own”, is a mischaracterization. A better characterization, would be to say: “DCVax-L helps methylated GBM patients more than it helps unmethylated patients, but all GBM patients are helped to live longer with DCVax-L”.

To not approve or make DCVax-L available for all GBM patients, methylated and unmethylated, would prevent unmethylated patients from the opportunity to be treated with DCVax-L along with poly-ICLC.

Here is what AI says:

[learningcurve2020]

I wrote that too fast so want to correct since you didn’t:

Assuming the results are to be trusted, you do understand in the Plll that ~87% of patients treated with L their cancer either progressed unaffected or was only slowed for a short period, right? And we have no idea what happened after the five year mark to those ~5% but it’s likely the cancer returned for most.

28 months as compared to what? SOC MOS is 20%.